| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: NENL |
| Security Type |
Common Stock |
| Lead Underwriter |
Credit Suisse First Boston |
| Days In Registration |
117 |
| Date Filed |
7-Apr-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Manufacture life science products and technologies for basic research, drug discovery, pharmaceutical development and other life science applications |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| President and CEO |
Russell D. Hays |
| Number of Employees |
541 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
